CN109716138B - 用于接触活化系统相关的疾病的蛋白生物标记 - Google Patents

用于接触活化系统相关的疾病的蛋白生物标记 Download PDF

Info

Publication number
CN109716138B
CN109716138B CN201780057056.2A CN201780057056A CN109716138B CN 109716138 B CN109716138 B CN 109716138B CN 201780057056 A CN201780057056 A CN 201780057056A CN 109716138 B CN109716138 B CN 109716138B
Authority
CN
China
Prior art keywords
protein
hae
disease
biomarker
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780057056.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109716138A (zh
Inventor
D·J·塞克斯顿
M·维斯瓦纳坦
R·福塞特
T·伽尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd, Dyax Corp filed Critical Takeda Pharmaceutical Co Ltd
Priority to CN202311187493.XA priority Critical patent/CN117192130A/zh
Publication of CN109716138A publication Critical patent/CN109716138A/zh
Application granted granted Critical
Publication of CN109716138B publication Critical patent/CN109716138B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780057056.2A 2016-09-16 2017-09-15 用于接触活化系统相关的疾病的蛋白生物标记 Active CN109716138B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311187493.XA CN117192130A (zh) 2016-09-16 2017-09-15 用于接触活化系统相关的疾病的蛋白生物标记

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395712P 2016-09-16 2016-09-16
US62/395,712 2016-09-16
US201762518492P 2017-06-12 2017-06-12
US62/518,492 2017-06-12
PCT/US2017/051749 WO2018053244A1 (en) 2016-09-16 2017-09-15 Protein biomarkers for diseases associated with the contact activation system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311187493.XA Division CN117192130A (zh) 2016-09-16 2017-09-15 用于接触活化系统相关的疾病的蛋白生物标记

Publications (2)

Publication Number Publication Date
CN109716138A CN109716138A (zh) 2019-05-03
CN109716138B true CN109716138B (zh) 2023-10-03

Family

ID=59974881

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780057056.2A Active CN109716138B (zh) 2016-09-16 2017-09-15 用于接触活化系统相关的疾病的蛋白生物标记
CN202311187493.XA Pending CN117192130A (zh) 2016-09-16 2017-09-15 用于接触活化系统相关的疾病的蛋白生物标记

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311187493.XA Pending CN117192130A (zh) 2016-09-16 2017-09-15 用于接触活化系统相关的疾病的蛋白生物标记

Country Status (12)

Country Link
US (2) US11815516B2 (https=)
EP (1) EP3513196B1 (https=)
JP (4) JP7225089B2 (https=)
KR (3) KR102806918B1 (https=)
CN (2) CN109716138B (https=)
AU (3) AU2017325983B2 (https=)
BR (1) BR112019005179A2 (https=)
CA (1) CA3037154A1 (https=)
CO (1) CO2019002599A2 (https=)
IL (2) IL265195B2 (https=)
MX (2) MX2019002932A (https=)
WO (1) WO2018053244A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017325986B2 (en) 2016-09-16 2023-12-14 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
CN113092769A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液补体c4-a及其多肽片段在过敏性疾病中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015061183A1 (en) * 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
WO2015112578A1 (en) * 2014-01-21 2015-07-30 Dyax Corp. Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
CN105073778A (zh) * 2013-01-20 2015-11-18 戴埃克斯有限公司 缓激肽介导的病症的评估和治疗
CN105377894A (zh) * 2013-06-04 2016-03-02 瑞泽恩制药公司 以il-4r抑制剂治疗过敏症及强化过敏原特异性免疫治疗的方法
CN105452860A (zh) * 2013-01-20 2016-03-30 戴埃克斯有限公司 Pkal-介导的病症的评估、测定和治疗
CN105874332A (zh) * 2013-10-21 2016-08-17 戴埃克斯有限公司 自身免疫性疾病的诊断和治疗

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT739355E (pt) 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP2001174463A (ja) * 1999-12-17 2001-06-29 Hsp Research Institute Inc 自己免疫疾患又は腫瘍の診断方法
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
JP4399593B2 (ja) * 2004-04-01 2010-01-20 国立大学法人 千葉大学 インフルエンザ脳症の検査法、及び、ヒト髄液中に発現するタンパク質からなるマーカ、診断薬、診断キット
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007059966A1 (en) * 2005-11-23 2007-05-31 Georg Dewald Detection and treatment of drug associated angioedema
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US20090104605A1 (en) * 2006-12-14 2009-04-23 Gary Siuzdak Diagnosis of sepsis
US20110159011A1 (en) 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
US8883153B2 (en) * 2009-03-27 2014-11-11 The Research for The State University of New York Methods for preventing and treating angioedema
EP3459564B1 (en) 2010-01-06 2021-10-27 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
US9102942B2 (en) * 2010-02-04 2015-08-11 EWHA University—Industry Collaboration Foundation Pharmaceutical composition for inhibiting abnormal proliferation of cells
JP2011226882A (ja) * 2010-04-19 2011-11-10 Kitasato Institute 泌尿器系疾患マーカー及びその抗体、並びに泌尿器系疾患診断用キット
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
WO2012170947A2 (en) * 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
US20130102486A1 (en) * 2011-10-20 2013-04-25 The Board Of Trustees Of The Leland Stanford Junior University Perp as a prognostic and diagnostic marker for dysplasia and cancer
EP3132053B1 (en) * 2014-04-15 2020-09-30 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Differential diagnosis of eczema and psoriasis
EA201990730A1 (ru) 2016-09-16 2019-08-30 Дайэкс Корп. Рнк-биомаркеры для наследственного ангионевротического отека
AU2017325986B2 (en) 2016-09-16 2023-12-14 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073778A (zh) * 2013-01-20 2015-11-18 戴埃克斯有限公司 缓激肽介导的病症的评估和治疗
CN105452860A (zh) * 2013-01-20 2016-03-30 戴埃克斯有限公司 Pkal-介导的病症的评估、测定和治疗
CN105377894A (zh) * 2013-06-04 2016-03-02 瑞泽恩制药公司 以il-4r抑制剂治疗过敏症及强化过敏原特异性免疫治疗的方法
WO2015061183A1 (en) * 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
CN105874332A (zh) * 2013-10-21 2016-08-17 戴埃克斯有限公司 自身免疫性疾病的诊断和治疗
WO2015112578A1 (en) * 2014-01-21 2015-07-30 Dyax Corp. Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
《Nuts and Bolts of laboratory evaluation of angioedema》;Farkas Henriette等;《Clinical reviews in Allergy and Immunology》;20160503;第51卷(第2期);摘要、表2、第143-144页 *
Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema;Zsuzsanna Kelemen等;《Clinical Immunology》;20091127;第134卷(第3期);354-358页 *
Hereditary Angioedema with Normal C1-INH (HAE Type III);Marc A. Riedl;《Clinical Commentary Review》;20130805;第1卷(第5期);427-432页 *
Nóra Veszeli等.Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency.《 Orphanet Journal of Rare Diseases》.2015,第10卷(第156期), *
接触系统生物学意义的再认识;刘发益等;《生理科学进展》;20000130;第31卷(第01期);7-12页 *
白细胞介素36及其在炎症性疾病中的作用;彭笑等;《中国药理学与毒理学杂志》;20150415;第29卷(第02期);317-322页 *
缓激肽在过敏性疾病发病机制中的作用;戴红良等;《中华临床免疫和变态反应杂志》;20141230;第08卷(第04期);306-310页 *
遗传性血管性水肿;赵伟等;《临床儿科杂志》;20100315;第28卷(第03期);297-299页 *
遗传性血管性水肿发病机制研究进展;崔玉艳等;《陕西医学杂志》;20071005;第36卷(第10期);1402-1403页 *

Also Published As

Publication number Publication date
JP7693788B2 (ja) 2025-06-17
AU2024201506A1 (en) 2024-03-28
CN109716138A (zh) 2019-05-03
WO2018053244A1 (en) 2018-03-22
AU2024201506B2 (en) 2025-12-18
EP3513196B1 (en) 2026-02-25
KR102806918B1 (ko) 2025-05-14
AU2017325983A1 (en) 2019-03-21
BR112019005179A2 (pt) 2019-07-02
CA3037154A1 (en) 2018-03-22
IL265195A (en) 2019-05-30
AU2017325983B2 (en) 2023-12-07
JP2024023904A (ja) 2024-02-21
JP7412616B2 (ja) 2024-01-12
IL265195B1 (en) 2024-10-01
EP3513196A1 (en) 2019-07-24
MX2019002932A (es) 2019-07-15
IL265195B2 (en) 2025-02-01
CO2019002599A2 (es) 2019-03-29
MX2024009782A (es) 2024-08-19
KR102513485B1 (ko) 2023-03-23
JP2019529906A (ja) 2019-10-17
US11815516B2 (en) 2023-11-14
JP7225089B2 (ja) 2023-02-20
NZ751193A (en) 2024-02-23
NZ792394A (en) 2025-07-25
JP2023058608A (ja) 2023-04-25
JP2025124852A (ja) 2025-08-26
KR20230044024A (ko) 2023-03-31
EP3513196C0 (en) 2026-02-25
KR20190053913A (ko) 2019-05-20
US20240142468A1 (en) 2024-05-02
KR20250073510A (ko) 2025-05-27
IL315799A (en) 2024-11-01
AU2026201253A1 (en) 2026-03-12
US20210285962A1 (en) 2021-09-16
CN117192130A (zh) 2023-12-08

Similar Documents

Publication Publication Date Title
JP7692508B2 (ja) 接触活性化系に関連する疾患の代謝物バイオマーカー
JP2025124852A (ja) 接触活性化系に関連する疾患のタンパク質バイオマーカー
HK40102769A (zh) 用於接触活化系统相关的疾病的蛋白生物标记
JP2025522757A (ja) ラナデルマブ治療のためのタンパク質バイオマーカー
HK40102782A (zh) 用於与接触活化系统相关的疾病的代谢产物生物标记
EA045712B1 (ru) Белковые биомаркеры заболеваний, ассоциированных с контактной системой активации

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210615

Address after: 1-1, sidingmu, xiudaocho, Central District, Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: DYAX Corp.

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment